Oral brexanolone's second Phase 3 swing at PPD, with BLOOM's site-controlled design the only test of whether the first miss was noise or signal

Lipocine is a clinical-stage company developing an oral targeted depression treatment for postpartum depression that is not yet approved.

Lipocine's oral brexanolone (LPCN 1154) missed its Phase 3 primary endpoint in postpartum depression, with the lone efficacy signal confined to a post hoc subgroup excluding a site where roughly 40% of treated participants had undetectable drug levels. The BLOOM Phase 3, now enrolling with strengthened site controls and FDA-informed design, is the single binary: a clean hit validates the post hoc interpretation; a second miss ends the PPD program. At approximately $1 million per month burn against $23 million cash, runway covers roughly 23 months, sufficient for BLOOM but leaving no cushion for a regulatory review cycle without additional financing.